Lopital strengthens its position through the acquisition of Culsana
Amsterdam, Oisterwijk, 15 June 2026 – Our portfolio company Lopital, a developer and supplier of innovative hygiene, transfer, and mobility solutions for the healthcare sector, has acquired Culsana. Through this strategic add-on acquisition, Lopital further expands its product portfolio and strengthens its position within the institutional healthcare market.
Joining Forces to Support Lopital’s Growth Strategy
Culsana develops and supplies medical seating and positioning support solutions for hospitals, healthcare institutions, and other public healthcare organizations. Since its founding in 2011, the company has built a strong position within the Dutch healthcare market.
Jan van Megen, CEO of Lopital: “With the addition of Culsana, we create immediate commercial synergies through our complementary product portfolios and shared customer base. This acquisition fits perfectly within our buy-and-build strategy, through which we continue to expand our offering with proprietary, complementary products for the healthcare sector.”
Since 2023, Holland Capital has supported Lopital as a shareholder in the company’s continued growth, both organically and through targeted acquisitions. The acquisition of Culsana marks another step in this strategy and contributes to Lopital’s further development as a leading partner for healthcare institutions in the Netherlands and abroad.
About Culsana
Founded in 2011 and headquartered in Schinnen, Culsana develops and supplies medical seating and positioning support solutions for hospitals, healthcare institutions, and other public healthcare organizations.
About Lopital
Founded in 1977, Lopital operates from its headquarters in Oisterwijk and is active in more than 25 countries. The company develops, assembles, and supplies high-quality hygiene, transfer, and mobility solutions for the healthcare sector./medexs.com/
About Holland Capital
For more than 40 years, Holland Capital has been investing responsibly and successfully in ambitious small and medium-sized enterprises (SMEs) in the Benelux and Germany. With offices in Amsterdam and Düsseldorf, Holland Capital focuses through specialized sector teams on the Healthcare and Technology sectors.
Holland Capital investeert in Pluggerz
Holland Capital investeert
in Pluggerz, marktleider in op maat gemaakte gehoorbescherming.
Emixa strengthens leadership with new CEO Jan Kritz to amplify client value and further accelerate growth
Our portfolio company Emixa strengthens leadership with new CEO Jan Kritz and COO Peter-Jan Simons to amplify client value and further accelerate growth.
Adjust breidt adviespropositie uit met overname van Accent Advies
Ons portfoliobedrijf Adjust Consulting (Adjust) breidt haar adviespropositie uit met de overname van Accent Advies.
Code-V verwelkomt nieuwe partners waaronder Holland Capital en lanceert landelijke Code-V Funding Roadmap
Code-V bestaat twee jaar en markeert deze mijlpaal met de toetreding van nieuwe ondertekenaars, waaronder Holland Capital.
Emixa neemt Nextage Group over om haar positie en focus op Digital Thread-leiderschap in de Nordics verder te versterken
Ons portfoliobedrijf Emixa, kondigt vandaag de overname aan van Nextage Group, één van de meest gerespecteerde Siemens Digital Industries Software-partners in de Nordics.
Semalytix haalt €5,7 miljoen groeikapitaal op om AI-platform voor patiëntinzichten verder op te schalen
Semalytix haalt groeikapitaal op om AI-platform voor patiëntinzichten verder op te schalen. De ronde werd geleid door Holland Capital.
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01
info@hollandcapital.nl





